A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on

• shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold),

• controlling asthma symptoms, and

• lowering the risk of asthma symptoms worsening in subjects with asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biota Scientific Management Pty Ltd

Criteria

Inclusion Criteria:

• Male and female subjects aged 18-70 years

• Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3

• Presumptive human rhinovirus infection

Exclusion Criteria:

• Current severe asthma exacerbation

• Severe asthma, GINA steps 4 or higher

• Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol

• Current smoker, ex-smoker of <1 year, or history of smoking >/=10 pack years.